The Company has been working for the last several months on improving 'ion optics' which is a critical component of the FAIMS system in order to better focus and maximize ion flow through the FAIMS cell 'keyhole'. Members of
In addition, Company engineers have been pushing forward development of its THC Breath Analyzer ('THCBA') which incorporates microfluidic sensor technology for the detection of 9-tetrahydrocannabinol ('THC') from breath. As announced in November, engineers have reduced the size of several components inside the THCBA for a more compact device, over the course of December, engineers have been further optimizing breath sample chamber design and tested additional sensors that work in conjunction with microfluidic sensor. Furthermore, the form factor (exterior) design of the THCBA will see additional refinements in due course. The Company reports that it has received notable media coverage from
About
Contact:
Email: info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing 'patent pending' technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
(C) 2020 Electronic News Publishing, source